A meta analysis of pulmonary vein isolation compared with additional ablation strategies for atrial fibrillation Authors: Muhammad M. Saleem, Muhammad Mudassar, Ajit Brar, Aleena Usman, Gurparvesh Goraya, Sameen B. Butt, Sohail Sodhi, Soumiya Ravi, Keerat Bains, Vijyawant Brar Published: 2025 ABSTRACT BackgroundPulmonary Vein Isolation (PVI) is considered to be the primary strategy for atrial fibrillation (AF) ablation. However, recurrence of AF and atrial tachycardia was observed to occur often after PVI, which led to the proposition of performing additional ablations such as linear lesions, left atrial (LA) posterior wall isolation, substrate modification, and electrocardiogram (EGM)-based approaches as add-ons to PVI or alternative strategies. While numerous randomized controlled trials have been conducted in this regard, the efficacy of these strategies compared with PVI alone has been ambiguous, with some trials showing significant improvement and others showing no superiority over PVI alone. Thus, a systematic review and meta-analysis were conducted to address this ambiguity and assess the efficacy of additional or alternative ablation strategies as compared with Pulmonary Vein Isolation alone.ObjectiveTo assess whether additional or alternative ablation strategies lead to better outcomes as compared with PVI alone.MethodsWe included only Randomized Controlled trials comparing Pulmonary Vein Isolation alone with Pulmonary Vein Isolation along with additional ablations or alternative ablation strategies in adults with persistent or paroxysmal Atrial Fibrillation. A thorough literature search was performed, and data were extracted in a tabulated form. A random-effects meta-analysis was performed, and afterwards, subgroup analyses were done to individually assess the efficacy of the most commonly used additional ablation strategies.ResultsA total of 65 studies with 10,760 participants were included. The mean age was 57 years, with approximately 68% male participants. The Additional Ablation group was associated with a significantly lower Risk Ratio (0.76, 95% CI: 0.70,0.82. P < 0.00001) of the composite primary outcome compared with PVI alone.ConclusionWhile additional ablation strategies beyond pulmonary vein isolation (PVI) have been associated with a trend towards improved outcomes, current evidence does not conclusively demonstrate superior efficacy over PVI alone. Further research is needed to clarify the potential benefits of adjunctive ablation approaches and to determine whether individualized strategies may improve outcomes in selected patient populations.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-025-05220-7. Introduction Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia [1]. It is a complex and heterogeneous arrhythmic dysregulation that might occur in the absence of known structural or electrophysiological anomalies. AF is characterized by tachyarrhythmia, which occurs due to abnormal electrical activity in the atria of the heart [2]. The occurrence of high-frequency excitation waves causes an increase in the heart rate, resulting in dyssynchrony in atrial and ventricular movements [2–4]. AF involves diverse pathophysiological causes, including cellular, molecular, and anatomical changes [5]. The likelihood of AF increases with several risk factors, including age, dietary patterns, physical activity, hormonal and metabolic perturbations, high blood pressure, underlying heart and lung disease, and genetics [6]. AF is estimated to affect about 33 million individuals globally, with the figures expected to double in 40 years. Significant association of AF has been found with adverse cardiovascular outcomes, including increased thromboembolic risk, myocardial infarction, stroke, and heart failure [5]. These events result in substantial morbidity and a 40–90% increased risk of mortality, becoming an important global health burden. Presumably, comorbid conditions play an important role in inducing histopathological changes in cardiac muscles that lead to the formation of a unique AF substrate or cause cardiomyopathy [7]. To overcome the complications, various interventional therapeutic approaches have been discovered, including risk factor modification, pharmacological drugs, pulmonary vein isolation (PVI), and additional ablation strategies [8]. Pulmonary vein isolation (PVI) techniques have been developed to achieve rhythm control by using catheter ablation approaches [9]. PVI has become a gold standard in the setting of recurrent AF, with electrical isolation of pulmonary veins (PVs) considered as a cornerstone of all ablation strategies [10]. The development of PVIs began with point-by-point radiofrequency ablation, which has now been advanced to single-shot devices such as cryoballoons with minimal side effects [11, 12]. Strategies such as Radiofrequency Myocardial Ablation, Cryoballoon Ablation, and Laser Balloon Ablation are widely used because of their comparative safety and non-invasiveness [10, 13]. A single PVI procedure success rate has been demonstrated to be 60–80% [14]. However, arrhythmia-free survival has been found to be in 50–75% of cases at 1-year post-ablation. This is followed by an increased risk of arrhythmia recurrence and atrial tachycardia in almost ~ 30% of the cases [15]. This necessitates additional ablation strategies such as Linear Lesions (LA), Ablation of Non-Pulmonary Vein Triggers (nPVI-te), Substrate Modification (SM), and Autonomic Modulation (AM) to maintain a stable sinus rhythm [16]. These add-on procedures are suggested to cause pulmonary reconnection or increased PV foci, making it a point of concern [17]. Multiple RCTs have been conducted to evaluate these add-on procedures, but no recent meta-analyses have been done to analyze these techniques collectively and evaluate their utility. Therefore, this systematic review and meta-analysis have been conducted to assess whether PVI alone or in combination with additional ablation strategies leads to better outcomes in AF termination. Methodology This study adheres to the PRISMA [96] and AMSTAR [97] guidelines. The methodology was carefully outlined before initiating the review process and was prospectively registered with PROSPERO (PROSPERO ID: CRD420251005557), with only minor amendments done to update the stage of the review. Data collection and search strategy We conducted a comprehensive literature search across multiple databases, including PubMed, Embase, Cochrane Library, Web of Science, and Scopus. The search strategy was developed using terms related to atrial fibrillation and catheter ablation techniques. Boolean operators (“AND,” “OR”) and wildcard operators (“*/#”) were used to refine the search. The primary search terms included “Pulmonary Vein Isolation”, “Posterior Wall Isolation”, “Complex Fractioned Atrial Electrogram”, “Linear Ablation,” “Non-Pulmonary Vein Trigger Isolation,” “Atrial Fibrillation”, and “Atrial Tachyarrhythmia,” among others. The complete search strategy is mentioned in the protocol that will be provided in the supplementary material. Selection criteria Eligible studies were those involving adult patients with either paroxysmal or non-paroxysmal atrial fibrillation, regardless of gender or geographic location. Studies comparing pulmonary vein Isolation (PVI) alone with PVI plus additional lesions as the technique for catheter ablation were included. The primary outcome of interest was the recurrence of atrial tachyarrhythmias. To ensure certainty of evidence, only randomized controlled trials (RCTs) published in English and in peer-reviewed journals were considered. Studies involving patients with prior ablation, whether catheter, surgical, or atrioventricular node ablation, were excluded. Studies lacking a comparison group, case reports, editorials, reviews, and studies with fewer than 10 participants were excluded as well. Non-peer-reviewed publications and studies not published in English were also deemed ineligible. Study endpoints and definitions The primary outcome was defined as the recurrence of atrial tachyarrhythmias, including but not limited to Atrial Fibrillation, Atrial flutter, and multifocal atrial tachycardia with a duration of ≥ 30 s recorded on an implantable loop recorder, pacemaker, defibrillator, ECG, or ambulatory-ECG during a minimum follow-up period of 6 months post catheter ablation (CA). Data extraction Following the database search, all identified records were uploaded to Rayyan.ai, where duplicate entries were automatically detected and removed using its built-in deduplication tool. The remaining studies underwent title and abstract screening to filter out irrelevant publications. Full-text versions of potentially eligible studies were then retrieved for further assessment. Two independent reviewers (MS and MM) conducted the screening and data extraction process. Any discrepancies were resolved through discussion and consultation with the corresponding author. Extracted data were systematically organized in an Excel spreadsheet, capturing key variables such as article title, publication year, study design, characteristics of study arms, participant demographics (age and gender), atrial fibrillation classification, catheter ablation techniques, comorbidities, and outcome measures. Once the selection process was complete, the chosen articles were analyzed by the authors, and the extracted data were tabulated using Google Sheets. To ensure accuracy, all entries were cross-checked for potential errors before finalizing the dataset. Quality assessment The Cochrane Collaboration Risk of Bias tool [98] was employed to evaluate the quality of the included studies. This assessment focused on five key domains, including randomization process, deviations from intended interventions, missing outcome data, measurement of outcomes, and selection of reported results. By analyzing these factors, the tool determined the overall risk of bias for each study, ensuring a systematic and transparent evaluation of methodological integrity. Statistical analyses The Relative Risk (RR) was used as the primary measure to evaluate the likelihood of recurrent atrial tachyarrhythmias between the experimental and control groups. A 95% Confidence Interval (CI) was applied to ensure statistical reliability. To synthesize the data, a Random Effects Meta-analysis with Inverse Variance was performed using RevMan software, generating a forest plot for visual representation. In order to assess the certainty of evidence, the GRADE [99] (Grading of Recommendations, Assessment, Development, and Evaluation) tool was employed. This framework categorizes evidence into four levels—high, moderate, low, and very low—based on how closely the estimated effect aligns with the true effect. Factors influencing the quality assessment included risk of bias, inconsistency, indirectness, imprecision, and publication bias. The I2 was utilized to evaluate heterogeneity, with interpretations guided by the Cochrane Handbook of Systematic Reviews. Inconsistency was quantified using the I² index, where values exceeding 50% indicated substantial variability. However, the significance of heterogeneity depended on the number of studies included, given the random effects model. Finally, a funnel plot was constructed to visually examine potential publication bias, ensuring a comprehensive assessment of study reliability. Results Study selection and characteristics After eliminating duplicate entries and automated exclusions, two researchers carefully reviewed a collection of 85 studies sourced from multiple databases. Independently, both investigators (AU and MM) assessed the titles of these publications to determine their relevance. If a title fulfilled all the predefined inclusion criteria and aligned with the core research objective, the full-text version was retrieved for further evaluation. From this initial group, 65 studies satisfied the preliminary selection criteria. All 65 of these were pertinent and had abstracts readily accessible and were incorporated into the final analysis. To visually represent the selection process, an R package and Shiny app [100] were employed to generate a PRISMA 2020-compliant flow diagram [96]. (Fig. 1). The list of excluded studies will be provided in the supplementary material. Fig. 1PRISMA flow diagram illustrating the study selection process PRISMA flow diagram illustrating the study selection process Relevant study data including Year of Publication, Type of study, Mean/Median Age, Sex, total number of participants, Comorbid conditions such as Hypertension, Diabetes, Obesity, number of participants in each group, interventions utilized in the control and experimental groups, and the results/outcomes reported by the study aiuthors were then extracted by two reviewers (AJ and SS), and is presented in the table (Table 1) below: Table 1Study characteristics and outcomes. PVI = pulmonary vein Isolation, nPVI-te = non-pulmonary vein trigger isolation/ablation, SM = substrate Modification, CFE/CFAE = Complex fractionated atrial Electrogram, PVAI = pulmonary vein antrum Isolation, LA = Linear Ablation, AM = Autonomic Modulation, LVA = Low voltage Areas, CPVI = Circumferential pulmonary vein Isolation, GP = Ganglionated Plexus, SVI = Superior Vena Cava Isolation, PWI = Posterior wall Isolation, RL = Roof line ablationAuthorPublication YearType of StudyTotal ParticipantsAge, Mean or MedianSex (% male & female)ComorbiditiesParticipants per GroupType of AFControl Group(s)Experimental Group(s)ResultsAhn J[31]2022Randomized Controlled Trial10065.6 ± 8.7 years84% malesHypertension (83%), Diabetes Mellitus (43%)PVI: 50, PVI + nPVI-Te: 50PersistentPVIPVI + nPVI-TeEvents inexperimental:12Events in control: 23Arbelo E[32]2014Randomized Controlled Trial12055 ± 11 years71% malesstroke (0.8%), CHA2DS2-VASc ≥ 1 (52.5%)PVI + LA: 59, PVI: 61ParoxysmalPVIPVI + LAEvents in experimental: 24Events in control: 27Aryana A[33]2018Multicenter Study390Mean age 67 years65% malesHypertension (75.5%), Diabetes Mellitus (21.5%), Coronary Artery Disease (21.5%)PVI: 168, PVI + nPVI-TeI: 222PersistentPVIPVI + nPVI-TeEvents in experimental: 66Events in control: 98Aryana A[34]2021Multicenter Randomized Single-Blind Study11068.5 ± 8.5 years62% malesHypertension (65.5%), Diabetes Mellitus (26%), Coronary Artery Disease (11.5%)PVI: 55, PVI + PWI: 55Persistent/Long-standingPVIPVI + PWIEvents in experimental: 14Events in control: 25Atienza F[35]2014Prospective Multicenter Single-Blinded Study11354 ± 10 years20% femaleHypertension (39%), Diabetes Mellitus (7.8%)CPVI: 58, CPVI + CFAE: 55Paroxysmal, PersistentCPVICPVI + CFAEEvents in experimental: 10Events in control: 12Bisignani A[36]2021Journal Article8067.8 ± 9 years62% malesHypertension (63%), Diabetes Mellitus (18.7%), Coronary Artery Disease (11.4%)PVI: 50, PVI + LAPWI: 30ParoxysmalPVIPVI + PWIEvents in experimental: 3Events in control: 6Bisbal F[37]2020Randomized Clinical Trial15558.5 ± 10 years71% malesHypertension (50%),Diabetes (9%)PVI: 76PVI + SM: 79Paroxysmal, PersistentPVIPVI + SMEvents in experimental: 22Events in control: 21Berger[38]2019Prospective,randomized trial24059 ± 8 years73% malesHypertension (42.5%). Diabetes (7%)PVI: 120PVI + AM: 120Paroxysmal or PersistentPVIPVI + AMEvents in experimental: 53Events in control: 53Chauhan VS[39]2020Randomized Controlled Pilot8061.6 ± 10 years75% malesHypertension (47%), Diabetes Mellitus (5%), Coronary Artery Disease (2%)PVI: 41, PVI + SM: 39Paroxysmal or PersistentPVIPVI + SMEvents in experimental: 10Events in control: 20Chen H[40]2023Randomized Clinical Trial41470.5 ± 4.4 years50% malesHypertension (62%), Diabetes Mellitus (17%), Coronary Artery Disease (23.5%)CPVI: 205, CPVI + LVA: 209ParoxysmalCPVICPVI + LVAEvents in experimental: 31Events in control: 49Chen M[41]2011Randomized Controlled Trial11856.0 ± 11.2years67% malesHypertension (23%), Diabetes Mellitus (7.5%), Coronary Artery Disease (5%)PVAI: 60, CFE: 58ParoxysmalPVAICFEEvents in experimental: 25Events in control: 17Corrado A[42]2010Prospective randomized study29456 years73.8% malesHypertension (64%)PVI: 160nPVI-Te: 134Paroxysmal, Persistent, PermanentPVInPVI-TeEvents in experimental: 26Events in control: 42Da Costa A[43]2015Prospective Randomized Study10056 ± 9 years17% femaleArterial hypertension (32%), Diabetes mellitus (4%)PVI: 49, PVI + SVCI: 51ParoxysmalPVIPVI + SVCIEvents in experimental: 6Events in control: 9Deisenhofer I[44]2009Randomized Controlled Trial6557 ± 10 years37% malesStructural heart disease (31%)PVI: 31, PVI + CFAE: 34ParoxysmalPVIPVI + CFAEEvents in experimental: 3Events in control: 4Di Biase L[45]2009Randomized Controlled Trial6957–59.9.9 years82% malesHypertension (36%)PVAI: 35, PVAI + CFAE: 34ParoxysmalPVAIPVAI + CFAEEvents in experimental: 3Events in control: 4Elayi[46]2008Prospective multicenter randomized study9759.1 years66% malesHypertension (51%),Heart Disease (43.6%)PVI: 48PVI + SM: 49PermanentPVIPVI + SMEvents in experimental: 19Events in control: 30Fassini G[47]2005Randomized Controlled Trial18755.5 ± 9.1 years80% malesStructural Heart Disease (5.8%)PVI: 92, PVI + LA: 95Paroxysmal or PersistentPVIPVI + LAEvents in experimental: 28Events in control: 43Faustino M[48]2015Multicenter Randomized Controlled Trial15062.8 ± 8.7 years61.3% malesHypertension (69.3%), Diabetes (23.3%)PVI: 75, PVI + SM: 75ParoxysmalPVIPVI + SMEvents in experimental: 20Events in control: 35Fink T[49]2017Randomized Controlled Trial11861.5 ± 9.729% femalesHypertension (54%), Diabetes mellitus (8%), Valvular disease (12%), Coronary Artery Disease (9%)PVI: 61, Substrate-modification: 57PersistentPVISubstrate-modificationEvents in experimental: 32Events in control: 33Gaita F[50]2008Randomized Controlled Trial204median age 55 years79.4% malesstructural heart disease (14%)PVI: 102, PVI + LA: 102Paroxysmal, Persistent/PermanentPVIPVI + LAEvents in experimental: 20Events in control: 50Gavin[51]2012Prospective Randomized Study42Mean age 67.5 years71% malesHypertension (38%)PVAI: 22, PVAI + LA: 20ParoxysmalPVAIPVAI + LAEvents in experimental: 10Events in control: 5Haïssaguerre M[52]2004Randomized Controlled Trial7053.0 ± 8.5 years74% malesHypertension (24%)PV isolation: 35, PV isolation + LA: 35PersistentPV isolationPV isolation + LAEvents in experimental: 6Events in control: 9Hocini M[53]2005Randomized Controlled Trial9055 ± 9 years78.8% malesstructural heart disease (28%)PV isolation: 45, PV isolation + LA: 45ParoxysmalPV isolationPV isolation + LAEvents in experimental: 6Events in control: 14Huo Y[54]2022Randomized Trial32466 ± 10 years67% malesHypertension (82%), Diabetes Mellitus (25%), Coronary Artery Disease (29%)PVI only: 163, PVI + SM: 161PersistentPVI onlyPVI + SMEvents in experimental: 56Events in control: 82Hwang[55]2021Randomized Trial5058.4 ± 9.5 years86% malesHypertension (50%), Diabetes Mellitus (18%)PVI: 25PVI + SM: 25PersistentPVIPVI + SMEvents in experimental: 4Events in control: 14Kang KW[56]2014Randomized Controlled Trial20056.8 ± 11.7 years74.5% malesHypertension (47%), Diabetes (14%)CPVI: 100, CPVI + SVC-L: 100ParoxysmalCPVICPVI + SVC-LEvents in experimental: 6Events in control: 27Katritsis DG[57]2011Randomized Controlled Trial6754.3 ± 11.5 years23.4% femalesHypertension (53.9%)PV isolation: 34, GP + PV isolation: 33ParoxysmalPV isolationGP + PV isolationEvents in experimental: 5Events in control: 13Katritsis DG[58]2013Multicenter Randomized Controlled Trial160mean age 56 years66% malesArterial Hypertension (76%), Diabetes (3.3%)PVI: 78, PVI + GP: 82ParoxysmalPVIPVI + GPEvents in experimental: 21Events in control: 34Khaykin Y[59]2009Multicenter Randomized Controlled Trial6055.5 ± 8.1 years78.5% malesHypertension (30%), Diabetes (5%)CPVA: 30, PVAI: 30ParoxysmalCPVAPVAIEvents in experimental: 13Events in control: 22Kim D[60]2022Prospective Randomised Trial15059.576.7% malesHypertension (44%)Diabetes (15.3%)PVI: 75nPVI-Te: 75Persistent AFPVInPVI-TeEvents in experimental: 23Events in control: 23Kim TH[61]2015Randomized Controlled Trial10056.4 ± 11.6 years75% malesHeart failure (3%), Hypertension (38%), stroke/TIA (17%)CPVI: 50, catheter Dallas lesion: 50ParoxysmalCPVICatheter Dallas lesion (CPVI + additional linear ablation)Events in experimental: 8Events in control: 6Kircher S[62]2017Randomized Controlled Trial60Median age 62.5 years62% MalesHypertension (80%)PVI: 35PVI + SM: 25Paroxysmal and persistentPVIPVI + SMEvents in experimental: 7Events in control: 19Kistler PM[63]2023Randomized Clinical Trial338median age 65.6 years76.9% malesObesity (65%), Hypertension (47%), Diabetes (10.35%), ischemic heart disease (12.2%)PVI with PWI: 170, PVI alone: 168PersistentPVI alonePVI with PWIEvents in experimental: 81Events in control: 78Kiuchi MG[64]2017Randomized Controlled Trial13557.6 ± 5.8 years79.5% malesDiabetes Mellitus (26%)PVI : 96, PVI + AM: 39ParoxysmalPVIPVI + AMEvents in experimental: 15Events in control: 59Kiuchi[65]2016Randomized Controlled Trial4567 ± 964.5% malesHypertension (100%),Diabetes (65%)PVI: 24PVI + AM: 21Paroxysmal, PersistentPVIPVI + AMEvents in experimental: 5Events in control: 18Lee JM[66]2019Randomized Controlled Trial21758.7 ± 10.8 years83.1% malesHistory of heart failure (22.7%), Hypertension (46.9%)CPVI group: 109, nPVI-te group: 108PersistentCPVICPVI + nPVI-teEvents in experimental: 29Events in control: 26Lim TW[67]2012Randomized Controlled Trial22058 ± 10 years82% malesSRI: 110, WAI: 110Paroxysmal, Persistent/Longstanding PersistentWide Antral PVIPosterior Box IsolationEvents in experimental: 29Events in control: 43Lin YJ[68]2012Randomized Controlled Trial12665% malesHypertension (49%), Diabetes (12.5%)Group I: 63, Group II: 63ParoxysmalPVIPVI incorporating high-frequency AF nestsEvents in experimental: 13Events in control: 21Mamchur SE[69]2014Randomized Controlled Trial8356.2 ± 8.8 years60% malesHistory of myocardial infarction (11%)PVAI: 42, Extended PVAI: 41PersistentPVAIExtended PVAIEvents in experimental: 13Events in control: 19Marrouche N[70]2022Randomized Controlled Trial84362.7 years21.1% femalesHypertension (58.6%)PVI: 422PVI + SM: 421PersistentPVIPVI + SMEvents in experimental: 175Events in control: 188Masuda M[71]2020Randomized Controlled Trial6268.97 ± 11.33 years50% femalesHypertension (68.7%), Diabetes Mellitus (23%)LVA ablation: 30, No ablation: 32ParoxysmalPVILVA ablationEvents in experimental: 17Events in control: 17Masuda M[72]2023Randomized Controlled Trial49664.1–65.6 years24% femalesHypertension (60.4%)PVI-alone: 248, PVI + LA: 248PersistentPVI-alonePVI + LAEvents in experimental: 72Events in control: 93Mun HS[73]2012Randomized Controlled Trial15655.8 ± 11.5 years76.3% maleshypertension (42.9%), diabetes (11.5%), history of ischaemic stroke (7.7%)CPVI: 52, CPVI + RL: 52, CPVI + PostBox: 52ParoxysmalCPVICPVI + Posterior Box IsolationCPVI + RLEvents in experimental: 21Events in control: 6Nührich JM[74]2014Randomized Controlled Trial6861.1 ± 2.0 years38% femalesHypertension (54.5%)PVI-alone: 33, PVI + CFAE: 35ParoxysmalPVI-alonePVI + CFAEEvents in experimental: 13Events in control: 11Oral H[75]2009Randomized Controlled Trial10060 ± 9 years20% female,80% maleStructural Heart Disease (16.6%),Hypertensive Heart Disease (60%)APVI + CFAE ablation: 50APVI alone: 50Long-lasting PersistentAPVI alonePVI + CFAE ablationEvents in experimental: 33Events in control: 32Pak HN[76]2020Randomized Controlled Trial11460.1 ± 9.9 years71.9% maleshypertension (50.9%), history of heart failure (20.2%)CPVI: 57,nPVI-te: 57Persistent to ParoxysmalCPVInPVI-teEvents in experimental: 16Events in control: 18Pappone C[77]2018Randomized Controlled Trial8161.5 ± 10.6 years74% malesHypertension (48.5%), Diabetes (10%)Mapping group: 41, Control group: 40PersistentModified circumferential PV ablationRRa + Modified circumferential PV ablationEvents in experimental: 11Events in control: 20Pappone C[78]2004Randomized Controlled Trial56056.5 ± 7.3 years52% malesCoronary Artery Disease (15%)CPVA: 280, nPVI-te: 280ParoxysmalCPVAnPVI-teEvents in experimental: 36Events in control: 41Pokushalov E[79]2012Randomized Controlled Trial2756.5 ± 8.4 years78% malesDiabetes Mellitues (11%)PVI-only: 14, PVI + Renal Denervation: 13Paroxysmal or PersistentPVI-onlyPVI + Renal DenervationEvents in experimental: 4Events in control: 10Pokushalov E[80]2014Meta analysis8056 ± 6 years68.6% malesCoronary Artery Disease (11.2%)PVI: 39PVI + AM: 41Paroxysmal or PersistentPVIPVI + AMEvents in experimental: 15Events in control: 26Pontoppidan J[81]2009Multicenter Randomized Controlled Trial14956 ± 8 years71% malesHypertension (37.5%), Diabetes Mellitus (11.5%)PVI: 76, PVI + LA: 73ParoxysmalPVIPVI + LAEvents in experimental: 48Events in control: 52Romanov, Alexander[82]2015Randomized Clinical Trial8960.0 ± 5.5 years60.6% malesHypertension (79.5%), Diabetes Mellitus (22.5%)PVI-only: 50, PVI + LAA closure: 39 (6 crossed over to PVI-only)Paroxysmal or PersistentPVI-onlyPVI + Left atrial appendage occlusionEvents in experimental: 17Events in control: 17Sawhney N[83]2010Randomized Controlled Trial6658 ± 11 years72.7% malesHypertension (56%)PVI: 34, PVI + LA: 32ParoxysmalPVIPVI + LAEvents in experimental: 10Events in control: 13Sheikh[84]2007Randomized Controlled Trial10059 ± 11 years63% malesPVI: 50PVI + LA: 50ParoxysmalPVIPVI + LAEvents in experimental: 7Events in control: 21Steinberg JS[85]2020Multicenter Single-Blind Randomized Controlled Trial312median age 60 years60.3% malesDiabetes (11.2%)PVI: 158, PVI + Renal Denervation: 154ParoxysmalPVIPVI + Renal DenervationEvents in experimental: 43Events in control: 64Verma A[86]2015Randomized Controlled Trial58958–61 years78% malesHypertension (54%), Diabetes mellitus (10%), Coronary Artery Disease (7%)PVI: 67, PVI + complex electrogram: 263, PVI + linear ablation: 259PersistentPVIPVI + complex electrogram, PVI + linear ablationEvents in experimental: 248Events in control: 40Verma A[87]2010Multicenter Randomized Trial6657 ± 10 years74% male,26% femaleprior stroke/transient ischaemic attack (5%), coronary artery disease (7%), valvular heart disease (20%), heart failure (3%), and hypertension (45%)PVI + CFE: 34, PVI: 32Paroxysmal, PersistentPVIPVI + CFEEvents in experimental: 9Events in control: 17Verma A[88]2008Multicenter Evaluation Study3561 ± 9 years74% male, 26% femaleStructural Heart Disease (31.5%)PVAI alone: 21, PVAI + CFE: 14Paroxysmal, PersistentPVAI alonePVAI + CFEEvents in experimental: 2Events in control: 6Verma A[89]2007Controlled Clinical Trial20056 ± 11 years37% female, 63% maleHypertension (47%)Group I: 100, Group II: 100Paroxysmal, Persistent/PermanentPVAI onlyPVAI + Anterior Left atrial ablationEvents in experimental: 18Events in control: 28Vogler J[90]2015Randomized Controlled Trial15361.7 ± 10.2 years74% malesArterial Hypertension (80%), Valvular heart disease (4.5%), Coronary Artery Disease (21%)PVI: 78, Pvi + SM: 75PersistentPVIPVI + SMEvents in experimental: 75Events in control: 78Wang XH[91]2008Randomized Controlled Trial10666.0 ± 8.8 years54.7% malesHypertension (21%), Diabetes mellitus (0.95%)CPVI: 54, CPVI + SVCI: 52ParoxysmalCPVICPVI + SVCIEvents in experimental: 10Events in control: 12Willems S[92]2006Randomized Controlled Trial6259.17 ± 10.7 yearsHypertension (37%)PVI: 30, PVI + SM: 32PersistentPVIPVI + SMEvents in experimental: 13Events in control: 24Wynn GJ[93]2016Randomized Controlled Trial12261.9 ± 10.5 years68% malesPersistent AF (61%), Hypertension (58%), Previous MI (9%), Diabetes (6%)PVI: 61, PVI + LA: 61Persistent, Sustained ParoxysmalPVIPVI + LAEvents in experimental: 23Events in control: 20Yang G[94]2022Randomized Controlled Trial30060.5 ± 9.5 years68% malesHypertension (45%), Diabetes Mellitus (9%), Coronary Artery Disease (6.6%)CPVI: 150, CPVI + LVA: 150PersistentCPVICPVI + LVAEvents in experimental: 101Events in control: 101Yu HT[95]2017Multicenter Randomized Controlled Trial11360.4 ± 10.1 years75% malesHypertension (53.5%), Diabetes Mellitus (18.5%)PVI: 59, PVI + nPVI-te: 54Persistent converted to ParoxysmalPVIPVI + nPVI-teEvents in experimental: 28Events in control: 27 Table 1Study characteristics and outcomes. PVI = pulmonary vein Isolation, nPVI-te = non-pulmonary vein trigger isolation/ablation, SM = substrate Modification, CFE/CFAE = Complex fractionated atrial Electrogram, PVAI = pulmonary vein antrum Isolation, LA = Linear Ablation, AM = Autonomic Modulation, LVA = Low voltage Areas, CPVI = Circumferential pulmonary vein Isolation, GP = Ganglionated Plexus, SVI = Superior Vena Cava Isolation, PWI = Posterior wall Isolation, RL = Roof line ablationAuthorPublication YearType of StudyTotal ParticipantsAge, Mean or MedianSex (% male & female)ComorbiditiesParticipants per GroupType of AFControl Group(s)Experimental Group(s)ResultsAhn J[31]2022Randomized Controlled Trial10065.6 ± 8.7 years84% malesHypertension (83%), Diabetes Mellitus (43%)PVI: 50, PVI + nPVI-Te: 50PersistentPVIPVI + nPVI-TeEvents inexperimental:12Events in control: 23Arbelo E[32]2014Randomized Controlled Trial12055 ± 11 years71% malesstroke (0.8%), CHA2DS2-VASc ≥ 1 (52.5%)PVI + LA: 59, PVI: 61ParoxysmalPVIPVI + LAEvents in experimental: 24Events in control: 27Aryana A[33]2018Multicenter Study390Mean age 67 years65% malesHypertension (75.5%), Diabetes Mellitus (21.5%), Coronary Artery Disease (21.5%)PVI: 168, PVI + nPVI-TeI: 222PersistentPVIPVI + nPVI-TeEvents in experimental: 66Events in control: 98Aryana A[34]2021Multicenter Randomized Single-Blind Study11068.5 ± 8.5 years62% malesHypertension (65.5%), Diabetes Mellitus (26%), Coronary Artery Disease (11.5%)PVI: 55, PVI + PWI: 55Persistent/Long-standingPVIPVI + PWIEvents in experimental: 14Events in control: 25Atienza F[35]2014Prospective Multicenter Single-Blinded Study11354 ± 10 years20% femaleHypertension (39%), Diabetes Mellitus (7.8%)CPVI: 58, CPVI + CFAE: 55Paroxysmal, PersistentCPVICPVI + CFAEEvents in experimental: 10Events in control: 12Bisignani A[36]2021Journal Article8067.8 ± 9 years62% malesHypertension (63%), Diabetes Mellitus (18.7%), Coronary Artery Disease (11.4%)PVI: 50, PVI + LAPWI: 30ParoxysmalPVIPVI + PWIEvents in experimental: 3Events in control: 6Bisbal F[37]2020Randomized Clinical Trial15558.5 ± 10 years71% malesHypertension (50%),Diabetes (9%)PVI: 76PVI + SM: 79Paroxysmal, PersistentPVIPVI + SMEvents in experimental: 22Events in control: 21Berger[38]2019Prospective,randomized trial24059 ± 8 years73% malesHypertension (42.5%). Diabetes (7%)PVI: 120PVI + AM: 120Paroxysmal or PersistentPVIPVI + AMEvents in experimental: 53Events in control: 53Chauhan VS[39]2020Randomized Controlled Pilot8061.6 ± 10 years75% malesHypertension (47%), Diabetes Mellitus (5%), Coronary Artery Disease (2%)PVI: 41, PVI + SM: 39Paroxysmal or PersistentPVIPVI + SMEvents in experimental: 10Events in control: 20Chen H[40]2023Randomized Clinical Trial41470.5 ± 4.4 years50% malesHypertension (62%), Diabetes Mellitus (17%), Coronary Artery Disease (23.5%)CPVI: 205, CPVI + LVA: 209ParoxysmalCPVICPVI + LVAEvents in experimental: 31Events in control: 49Chen M[41]2011Randomized Controlled Trial11856.0 ± 11.2years67% malesHypertension (23%), Diabetes Mellitus (7.5%), Coronary Artery Disease (5%)PVAI: 60, CFE: 58ParoxysmalPVAICFEEvents in experimental: 25Events in control: 17Corrado A[42]2010Prospective randomized study29456 years73.8% malesHypertension (64%)PVI: 160nPVI-Te: 134Paroxysmal, Persistent, PermanentPVInPVI-TeEvents in experimental: 26Events in control: 42Da Costa A[43]2015Prospective Randomized Study10056 ± 9 years17% femaleArterial hypertension (32%), Diabetes mellitus (4%)PVI: 49, PVI + SVCI: 51ParoxysmalPVIPVI + SVCIEvents in experimental: 6Events in control: 9Deisenhofer I[44]2009Randomized Controlled Trial6557 ± 10 years37% malesStructural heart disease (31%)PVI: 31, PVI + CFAE: 34ParoxysmalPVIPVI + CFAEEvents in experimental: 3Events in control: 4Di Biase L[45]2009Randomized Controlled Trial6957–59.9.9 years82% malesHypertension (36%)PVAI: 35, PVAI + CFAE: 34ParoxysmalPVAIPVAI + CFAEEvents in experimental: 3Events in control: 4Elayi[46]2008Prospective multicenter randomized study9759.1 years66% malesHypertension (51%),Heart Disease (43.6%)PVI: 48PVI + SM: 49PermanentPVIPVI + SMEvents in experimental: 19Events in control: 30Fassini G[47]2005Randomized Controlled Trial18755.5 ± 9.1 years80% malesStructural Heart Disease (5.8%)PVI: 92, PVI + LA: 95Paroxysmal or PersistentPVIPVI + LAEvents in experimental: 28Events in control: 43Faustino M[48]2015Multicenter Randomized Controlled Trial15062.8 ± 8.7 years61.3% malesHypertension (69.3%), Diabetes (23.3%)PVI: 75, PVI + SM: 75ParoxysmalPVIPVI + SMEvents in experimental: 20Events in control: 35Fink T[49]2017Randomized Controlled Trial11861.5 ± 9.729% femalesHypertension (54%), Diabetes mellitus (8%), Valvular disease (12%), Coronary Artery Disease (9%)PVI: 61, Substrate-modification: 57PersistentPVISubstrate-modificationEvents in experimental: 32Events in control: 33Gaita F[50]2008Randomized Controlled Trial204median age 55 years79.4% malesstructural heart disease (14%)PVI: 102, PVI + LA: 102Paroxysmal, Persistent/PermanentPVIPVI + LAEvents in experimental: 20Events in control: 50Gavin[51]2012Prospective Randomized Study42Mean age 67.5 years71% malesHypertension (38%)PVAI: 22, PVAI + LA: 20ParoxysmalPVAIPVAI + LAEvents in experimental: 10Events in control: 5Haïssaguerre M[52]2004Randomized Controlled Trial7053.0 ± 8.5 years74% malesHypertension (24%)PV isolation: 35, PV isolation + LA: 35PersistentPV isolationPV isolation + LAEvents in experimental: 6Events in control: 9Hocini M[53]2005Randomized Controlled Trial9055 ± 9 years78.8% malesstructural heart disease (28%)PV isolation: 45, PV isolation + LA: 45ParoxysmalPV isolationPV isolation + LAEvents in experimental: 6Events in control: 14Huo Y[54]2022Randomized Trial32466 ± 10 years67% malesHypertension (82%), Diabetes Mellitus (25%), Coronary Artery Disease (29%)PVI only: 163, PVI + SM: 161PersistentPVI onlyPVI + SMEvents in experimental: 56Events in control: 82Hwang[55]2021Randomized Trial5058.4 ± 9.5 years86% malesHypertension (50%), Diabetes Mellitus (18%)PVI: 25PVI + SM: 25PersistentPVIPVI + SMEvents in experimental: 4Events in control: 14Kang KW[56]2014Randomized Controlled Trial20056.8 ± 11.7 years74.5% malesHypertension (47%), Diabetes (14%)CPVI: 100, CPVI + SVC-L: 100ParoxysmalCPVICPVI + SVC-LEvents in experimental: 6Events in control: 27Katritsis DG[57]2011Randomized Controlled Trial6754.3 ± 11.5 years23.4% femalesHypertension (53.9%)PV isolation: 34, GP + PV isolation: 33ParoxysmalPV isolationGP + PV isolationEvents in experimental: 5Events in control: 13Katritsis DG[58]2013Multicenter Randomized Controlled Trial160mean age 56 years66% malesArterial Hypertension (76%), Diabetes (3.3%)PVI: 78, PVI + GP: 82ParoxysmalPVIPVI + GPEvents in experimental: 21Events in control: 34Khaykin Y[59]2009Multicenter Randomized Controlled Trial6055.5 ± 8.1 years78.5% malesHypertension (30%), Diabetes (5%)CPVA: 30, PVAI: 30ParoxysmalCPVAPVAIEvents in experimental: 13Events in control: 22Kim D[60]2022Prospective Randomised Trial15059.576.7% malesHypertension (44%)Diabetes (15.3%)PVI: 75nPVI-Te: 75Persistent AFPVInPVI-TeEvents in experimental: 23Events in control: 23Kim TH[61]2015Randomized Controlled Trial10056.4 ± 11.6 years75% malesHeart failure (3%), Hypertension (38%), stroke/TIA (17%)CPVI: 50, catheter Dallas lesion: 50ParoxysmalCPVICatheter Dallas lesion (CPVI + additional linear ablation)Events in experimental: 8Events in control: 6Kircher S[62]2017Randomized Controlled Trial60Median age 62.5 years62% MalesHypertension (80%)PVI: 35PVI + SM: 25Paroxysmal and persistentPVIPVI + SMEvents in experimental: 7Events in control: 19Kistler PM[63]2023Randomized Clinical Trial338median age 65.6 years76.9% malesObesity (65%), Hypertension (47%), Diabetes (10.35%), ischemic heart disease (12.2%)PVI with PWI: 170, PVI alone: 168PersistentPVI alonePVI with PWIEvents in experimental: 81Events in control: 78Kiuchi MG[64]2017Randomized Controlled Trial13557.6 ± 5.8 years79.5% malesDiabetes Mellitus (26%)PVI : 96, PVI + AM: 39ParoxysmalPVIPVI + AMEvents in experimental: 15Events in control: 59Kiuchi[65]2016Randomized Controlled Trial4567 ± 964.5% malesHypertension (100%),Diabetes (65%)PVI: 24PVI + AM: 21Paroxysmal, PersistentPVIPVI + AMEvents in experimental: 5Events in control: 18Lee JM[66]2019Randomized Controlled Trial21758.7 ± 10.8 years83.1% malesHistory of heart failure (22.7%), Hypertension (46.9%)CPVI group: 109, nPVI-te group: 108PersistentCPVICPVI + nPVI-teEvents in experimental: 29Events in control: 26Lim TW[67]2012Randomized Controlled Trial22058 ± 10 years82% malesSRI: 110, WAI: 110Paroxysmal, Persistent/Longstanding PersistentWide Antral PVIPosterior Box IsolationEvents in experimental: 29Events in control: 43Lin YJ[68]2012Randomized Controlled Trial12665% malesHypertension (49%), Diabetes (12.5%)Group I: 63, Group II: 63ParoxysmalPVIPVI incorporating high-frequency AF nestsEvents in experimental: 13Events in control: 21Mamchur SE[69]2014Randomized Controlled Trial8356.2 ± 8.8 years60% malesHistory of myocardial infarction (11%)PVAI: 42, Extended PVAI: 41PersistentPVAIExtended PVAIEvents in experimental: 13Events in control: 19Marrouche N[70]2022Randomized Controlled Trial84362.7 years21.1% femalesHypertension (58.6%)PVI: 422PVI + SM: 421PersistentPVIPVI + SMEvents in experimental: 175Events in control: 188Masuda M[71]2020Randomized Controlled Trial6268.97 ± 11.33 years50% femalesHypertension (68.7%), Diabetes Mellitus (23%)LVA ablation: 30, No ablation: 32ParoxysmalPVILVA ablationEvents in experimental: 17Events in control: 17Masuda M[72]2023Randomized Controlled Trial49664.1–65.6 years24% femalesHypertension (60.4%)PVI-alone: 248, PVI + LA: 248PersistentPVI-alonePVI + LAEvents in experimental: 72Events in control: 93Mun HS[73]2012Randomized Controlled Trial15655.8 ± 11.5 years76.3% maleshypertension (42.9%), diabetes (11.5%), history of ischaemic stroke (7.7%)CPVI: 52, CPVI + RL: 52, CPVI + PostBox: 52ParoxysmalCPVICPVI + Posterior Box IsolationCPVI + RLEvents in experimental: 21Events in control: 6Nührich JM[74]2014Randomized Controlled Trial6861.1 ± 2.0 years38% femalesHypertension (54.5%)PVI-alone: 33, PVI + CFAE: 35ParoxysmalPVI-alonePVI + CFAEEvents in experimental: 13Events in control: 11Oral H[75]2009Randomized Controlled Trial10060 ± 9 years20% female,80% maleStructural Heart Disease (16.6%),Hypertensive Heart Disease (60%)APVI + CFAE ablation: 50APVI alone: 50Long-lasting PersistentAPVI alonePVI + CFAE ablationEvents in experimental: 33Events in control: 32Pak HN[76]2020Randomized Controlled Trial11460.1 ± 9.9 years71.9% maleshypertension (50.9%), history of heart failure (20.2%)CPVI: 57,nPVI-te: 57Persistent to ParoxysmalCPVInPVI-teEvents in experimental: 16Events in control: 18Pappone C[77]2018Randomized Controlled Trial8161.5 ± 10.6 years74% malesHypertension (48.5%), Diabetes (10%)Mapping group: 41, Control group: 40PersistentModified circumferential PV ablationRRa + Modified circumferential PV ablationEvents in experimental: 11Events in control: 20Pappone C[78]2004Randomized Controlled Trial56056.5 ± 7.3 years52% malesCoronary Artery Disease (15%)CPVA: 280, nPVI-te: 280ParoxysmalCPVAnPVI-teEvents in experimental: 36Events in control: 41Pokushalov E[79]2012Randomized Controlled Trial2756.5 ± 8.4 years78% malesDiabetes Mellitues (11%)PVI-only: 14, PVI + Renal Denervation: 13Paroxysmal or PersistentPVI-onlyPVI + Renal DenervationEvents in experimental: 4Events in control: 10Pokushalov E[80]2014Meta analysis8056 ± 6 years68.6% malesCoronary Artery Disease (11.2%)PVI: 39PVI + AM: 41Paroxysmal or PersistentPVIPVI + AMEvents in experimental: 15Events in control: 26Pontoppidan J[81]2009Multicenter Randomized Controlled Trial14956 ± 8 years71% malesHypertension (37.5%), Diabetes Mellitus (11.5%)PVI: 76, PVI + LA: 73ParoxysmalPVIPVI + LAEvents in experimental: 48Events in control: 52Romanov, Alexander[82]2015Randomized Clinical Trial8960.0 ± 5.5 years60.6% malesHypertension (79.5%), Diabetes Mellitus (22.5%)PVI-only: 50, PVI + LAA closure: 39 (6 crossed over to PVI-only)Paroxysmal or PersistentPVI-onlyPVI + Left atrial appendage occlusionEvents in experimental: 17Events in control: 17Sawhney N[83]2010Randomized Controlled Trial6658 ± 11 years72.7% malesHypertension (56%)PVI: 34, PVI + LA: 32ParoxysmalPVIPVI + LAEvents in experimental: 10Events in control: 13Sheikh[84]2007Randomized Controlled Trial10059 ± 11 years63% malesPVI: 50PVI + LA: 50ParoxysmalPVIPVI + LAEvents in experimental: 7Events in control: 21Steinberg JS[85]2020Multicenter Single-Blind Randomized Controlled Trial312median age 60 years60.3% malesDiabetes (11.2%)PVI: 158, PVI + Renal Denervation: 154ParoxysmalPVIPVI + Renal DenervationEvents in experimental: 43Events in control: 64Verma A[86]2015Randomized Controlled Trial58958–61 years78% malesHypertension (54%), Diabetes mellitus (10%), Coronary Artery Disease (7%)PVI: 67, PVI + complex electrogram: 263, PVI + linear ablation: 259PersistentPVIPVI + complex electrogram, PVI + linear ablationEvents in experimental: 248Events in control: 40Verma A[87]2010Multicenter Randomized Trial6657 ± 10 years74% male,26% femaleprior stroke/transient ischaemic attack (5%), coronary artery disease (7%), valvular heart disease (20%), heart failure (3%), and hypertension (45%)PVI + CFE: 34, PVI: 32Paroxysmal, PersistentPVIPVI + CFEEvents in experimental: 9Events in control: 17Verma A[88]2008Multicenter Evaluation Study3561 ± 9 years74% male, 26% femaleStructural Heart Disease (31.5%)PVAI alone: 21, PVAI + CFE: 14Paroxysmal, PersistentPVAI alonePVAI + CFEEvents in experimental: 2Events in control: 6Verma A[89]2007Controlled Clinical Trial20056 ± 11 years37% female, 63% maleHypertension (47%)Group I: 100, Group II: 100Paroxysmal, Persistent/PermanentPVAI onlyPVAI + Anterior Left atrial ablationEvents in experimental: 18Events in control: 28Vogler J[90]2015Randomized Controlled Trial15361.7 ± 10.2 years74% malesArterial Hypertension (80%), Valvular heart disease (4.5%), Coronary Artery Disease (21%)PVI: 78, Pvi + SM: 75PersistentPVIPVI + SMEvents in experimental: 75Events in control: 78Wang XH[91]2008Randomized Controlled Trial10666.0 ± 8.8 years54.7% malesHypertension (21%), Diabetes mellitus (0.95%)CPVI: 54, CPVI + SVCI: 52ParoxysmalCPVICPVI + SVCIEvents in experimental: 10Events in control: 12Willems S[92]2006Randomized Controlled Trial6259.17 ± 10.7 yearsHypertension (37%)PVI: 30, PVI + SM: 32PersistentPVIPVI + SMEvents in experimental: 13Events in control: 24Wynn GJ[93]2016Randomized Controlled Trial12261.9 ± 10.5 years68% malesPersistent AF (61%), Hypertension (58%), Previous MI (9%), Diabetes (6%)PVI: 61, PVI + LA: 61Persistent, Sustained ParoxysmalPVIPVI + LAEvents in experimental: 23Events in control: 20Yang G[94]2022Randomized Controlled Trial30060.5 ± 9.5 years68% malesHypertension (45%), Diabetes Mellitus (9%), Coronary Artery Disease (6.6%)CPVI: 150, CPVI + LVA: 150PersistentCPVICPVI + LVAEvents in experimental: 101Events in control: 101Yu HT[95]2017Multicenter Randomized Controlled Trial11360.4 ± 10.1 years75% malesHypertension (53.5%), Diabetes Mellitus (18.5%)PVI: 59, PVI + nPVI-te: 54Persistent converted to ParoxysmalPVIPVI + nPVI-teEvents in experimental: 28Events in control: 27 Study characteristics and outcomes. PVI = pulmonary vein Isolation, nPVI-te = non-pulmonary vein trigger isolation/ablation, SM = substrate Modification, CFE/CFAE = Complex fractionated atrial Electrogram, PVAI = pulmonary vein antrum Isolation, LA = Linear Ablation, AM = Autonomic Modulation, LVA = Low voltage Areas, CPVI = Circumferential pulmonary vein Isolation, GP = Ganglionated Plexus, SVI = Superior Vena Cava Isolation, PWI = Posterior wall Isolation, RL = Roof line ablation Events in experimental:12 Events in control : 23 Events in experimental: 24 Events in control: 27 Events in experimental: 66 Events in control: 98 Events in experimental: 14 Events in control: 25 Events in experimental: 10 Events in control: 12 Events in experimental: 3 Events in control: 6 Hypertension (50%), Diabetes (9%) PVI: 76 PVI + SM: 79 Events in experimental: 22 Events in control: 21 Prospective, randomized trial PVI: 120 PVI + AM: 120 Events in experimental: 53 Events in control: 53 Events in experimental: 10 Events in control: 20 Events in experimental: 31 Events in control: 49 56.0 ± 11.2 years Events in experimental: 25 Events in control: 17 PVI: 160 nPVI-Te: 134 Events in experimental: 26 Events in control: 42 Events in experimental: 6 Events in control: 9 Events in experimental: 3 Events in control: 4 Events in experimental: 3 Events in control: 4 Hypertension (51%), Heart Disease (43.6%) PVI: 48 PVI + SM: 49 Events in experimental: 19 Events in control: 30 Events in experimental: 28 Events in control: 43 Events in experimental: 20 Events in control: 35 Events in experimental: 32 Events in control: 33 Events in experimental: 20 Events in control: 50 Events in experimental: 10 Events in control: 5 Events in experimental: 6 Events in control: 9 Events in experimental: 6 Events in control: 14 Events in experimental: 56 Events in control: 82 PVI: 25 PVI + SM: 25 Events in experimental: 4 Events in control: 14 Events in experimental: 6 Events in control: 27 Events in experimental: 5 Events in control: 13 Events in experimental: 21 Events in control: 34 Events in experimental: 13 Events in control: 22 Hypertension (44%) Diabetes (15.3%) PVI: 75 nPVI-Te: 75 Events in experimental: 23 Events in control: 23 Events in experimental: 8 Events in control: 6 Median age 62.5 years PVI: 35 PVI + SM: 25 Events in experimental: 7 Events in control: 19 Events in experimental: 81 Events in control: 78 Events in experimental: 15 Events in control: 59 Hypertension (100%), Diabetes (65%) PVI: 24 PVI + AM: 21 Events in experimental: 5 Events in control: 18 Events in experimental: 29 Events in control: 26 Events in experimental: 29 Events in control: 43 Events in experimental: 13 Events in control: 21 Events in experimental: 13 Events in control: 19 PVI: 422 PVI + SM: 421 Events in experimental: 175 Events in control: 188 Events in experimental: 17 Events in control: 17 Events in experimental: 72 Events in control: 93 CPVI + Posterior Box Isolation CPVI + RL Events in experimental: 21 Events in control: 6 Events in experimental: 13 Events in control: 11 20% female, 80% male Structural Heart Disease (16.6%), Hypertensive Heart Disease (60%) APVI + CFAE ablation: 50 APVI alone: 50 Events in experimental: 33 Events in control: 32 CPVI: 57, nPVI-te: 57 Events in experimental: 16 Events in control: 18 Events in experimental: 11 Events in control: 20 Events in experimental: 36 Events in control: 41 Events in experimental: 4 Events in control: 10 PVI: 39 PVI + AM: 41 Events in experimental: 15 Events in control: 26 Events in experimental: 48 Events in control: 52 Events in experimental: 17 Events in control: 17 Events in experimental: 10 Events in control: 13 PVI: 50 PVI + LA: 50 Events in experimental: 7 Events in control: 21 Events in experimental: 43 Events in control: 64 Events in experimental: 248 Events in control: 40 74% male, 26% female Events in experimental: 9 Events in control: 17 Events in experimental: 2 Events in control: 6 Events in experimental: 18 Events in control: 28 Events in experimental: 75 Events in control: 78 Events in experimental: 10 Events in control: 12 Events in experimental: 13 Events in control: 24 Events in experimental: 23 Events in control: 20 Events in experimental: 101 Events in control: 101 Events in experimental: 28 Events in control: 27 Data syntheses A total of 65 studies with 10,760 participants were included. The mean age was 57 years, with approximately 68% male participants. Among the studies reporting Hypertension, 57.9% of participants were hypertensive. Similarly, from the studies that reported diabetics, 19.2% of participants had diabetes. 14 studied utilized nPVI-te as the additional ablation technique, 16 utilized Linear Ablation, 8 used Autonomic Modulation, and 24 utilized Substrate Modification. The Additional Ablation group was associated with a significantly lower Risk Ratio (0.76, 95% CI: 0.70,0.82. P < 0.00001) of the composite primary outcome compared with PVI alone, as shown in the figure (Fig. 2) below. Heterogeneity amongst the studies was calculated to be moderate, at 56%. Moreover, subgroup analysis (Fig. 2) revealed that Autonomic Modulation was associated with the most favorable outcomes (RR: 0.61, 95% CI: 0.48,0.78. P < 0.0001), followed by Linear Ablation (RR: 0.72, 95% CI: 0.60,0.88. P < 0.001), nPVI-Te (RR: 0.76, 95% CI: 0.71,0.90. P = 0.0002), and Substrate Modification (RR: 0.83, 95% CI: 0.77,0.90. P < 0.00001). Fig. 2Forest Plot depicting the Risk Ratio of developing recurrent tachyarrhythmia between the experimental (Additional Ablation) and control (Pulmonary Vein Isolation only) groups. Also illustrated is the subgroup analysis based on the strategy of additional ablations (nPVI-te, Linear Ablation, Autonomic Modulation, SM) Forest Plot depicting the Risk Ratio of developing recurrent tachyarrhythmia between the experimental (Additional Ablation) and control (Pulmonary Vein Isolation only) groups. Also illustrated is the subgroup analysis based on the strategy of additional ablations (nPVI-te, Linear Ablation, Autonomic Modulation, SM) Subgroup analysis of PVI-Plus strategies for persistent atrial fibrillation A subgroup analysis was performed including studies assessing PVI-Plus strategies for persistent atrial fibrillation only (Fig. 3), which also yielded a lower risk of the composite primary outcome with the additional ablation group (RR : 0.79, 95% CI: 0.70, 0.90, p < 0.0001). Moderate heterogeneity was present between the studies with an I[2] value of 66%. Fig. 3Forest plot depicting the risk ratio of developing recurrent tachyarrhythmia between the experimental (additional ablation) and control (pulmonary vein isolation only) groups in patients with persistent atrial fibrillation Forest plot depicting the risk ratio of developing recurrent tachyarrhythmia between the experimental (additional ablation) and control (pulmonary vein isolation only) groups in patients with persistent atrial fibrillation Sensitivity analysis A leave-one-out sensitivity analysis was conducted to assess the influence of individual studies. The pooled effect size remained stable across iterations, suggesting that no single study unduly influenced the overall results. The same results were seen when sensitivity analysis was done for the persistent-Afib only subgroup. Risk of bias assessment To evaluate potential bias in the included Randomized Controlled Trials (RCTs), the Risk of Bias (RoB) tool was applied. This assessment examined five distinct domains, which were then used to determine the overall bias risk for each study. While most trials exhibited low to moderate bias across various domains, a high risk of bias was identified in areas related to blinding procedures, specifically allocation concealment and outcome assessment, due to the inherent nature of the studies. Two independent reviewers (AB and AU) conducted separate evaluations of each trial, and after thorough discussion, no discrepancies were found in their assessments. The results are illustrated in the table (Table 2) below: Table 2Reviewer’s assessment for risk of bias of included studies Table 2Reviewer’s assessment for risk of bias of included studies Reviewer’s assessment for risk of bias of included studies Publication bias assessment A funnel plot (Fig. 4) was generated to visually assess the precision of included studies and the potential for publication bias. The plot indicates high precision, suggesting that the studies are consistently distributed without significant asymmetry. This pattern implies a low risk of publication bias, reinforcing the reliability of the meta-analysis findings. Fig. 4Funnel plot for publication bias Funnel plot for publication bias Certainty assessment Using the GRADE tool, we concluded that the certainty of evidence for assessing the Risk ratio of having recurrent atrial tachyarrhythmia is high. This conclusion was reached after judging the evidence for risk of bias, imprecision, inconsistency, indirectness, and publication bias, all of which were found to be low for each of the included studies, except for risk of bias, which was moderate, but given the nature of interventions, was unavoidable and thus not deemed significant enough to affect the certainty of the results. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work the author(s) used [Grammarly.ai and copilot.ai] in order to [improve grammar and readability]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication. Discussion Atrial fibrillation (AF) results from abnormal atrial activity in the atria and is associated with various complications, including stroke [18]. Treatment focuses on controlling symptoms, reducing heart failure-related morbidity, preventing stroke, and recurrence [19]. Unlike traditional rate and rhythm control medications, catheter ablation has emerged as a newer treatment approach, involving the creation of lesions in areas responsible for triggering AF [20]. In 1998, M. Haïssaguerre conducted an electrophysiological study with 45 patients, identifying ectopic foci for tachycardia originating in both the right and left atrium, with 94% arising from the pulmonary veins, which could potentially trigger atrial fibrillation and be targeted for ablation [21]. This knowledge that most of the atrial premature beats originate in the pulmonary vein ostium, which is the direct precursor of atrial fibrillation, led to the widespread use of pulmonary vein isolation (PVI) as a viable treatment option. Traditionally, different ablation techniques have been used to isolate the pulmonary veins, but the data on their efficacy, especially in patients with persistent AF, has been insufficient, and since the population under study is extremely heterogeneous, recent studies have suggested utilizing additional ablation techniques to supplement PVI [30]. In this meta-analysis, we compared the efficacy of pulmonary vein isolation (PVI) alone with additional ablation strategies, including linear ablation, non-pulmonary vein trigger isolation/ablation, substrate modification, and autonomic modulation. The rationale for linear ablation is to disrupt wavelet circuits by reducing the available area for their propagation. Common linear lesions include the permitral line, roofline, mitral isthmus, and left atrial roof [22]. We also examined major non-pulmonary vein triggers for atrial fibrillation, such as the left atrial posterior wall and superior vena cava [23]. Given the influence of the autonomic nervous system on atrial electrophysiology, ganglionic and renal neuromodulation have been shown to reduce both the incidence and recurrence of AF[24], so these trials were also included in our analysis along with trials assessing Substrate modification using complex fractionated atrial electrograms, low-voltage area mapping, and MRI. Previous trials have reported mixed evidence regarding the efficacy of additional ablation strategies, and no clear consensus has been established on their effectiveness [25]. The STAR AF 2 trial was among the first to challenge the efficacy of additional ablation strategies in preventing atrial fibrillation (AF) [26]. This lack of efficacy might, in part, be attributed to the additional arrhythmogenic areas created by these ablation techniques, as there has been a growing concern about their potential proarrhythmic effects [27–29]. Subsequent studies, however, have provided evidence supporting the use of additional ablation strategies in managing AF. For instance, a trial by Huo et al. demonstrated favorable outcomes with pulmonary vein isolation (PVI) combined with substrate modification (SM). Similarly, studies conducted by Kaug et al., Ariana et al., and Pokushalov et al. reported decreased recurrence rates when PVI was supplemented with linear ablation, nPVI-te, and autonomic modulation, respectively, compared to PVI alone. In our meta-analysis, which included 65 studies encompassing 10,760 patients, we investigated whether combining PVI with additional ablation strategies offers superior outcomes compared to PVI alone. Our findings revealed that PVI combined with additional techniques was associated with a significantly lower risk of AF recurrence compared to PVI alone. Among the techniques analyzed, autonomic modulation (AM) demonstrated the lowest incidence of recurrence, with a relative risk of 0.61 compared to PVI alone, followed by linear ablation (LA) and nPVI-te. While SM was associated with the highest risk of recurrence among the additional techniques, this risk was still lower than that observed with PVI alone. These findings align with previous meta-analyses, which have also reported that PVI alone may not be sufficient for optimal long-term AF suppression, and additional techniques are necessary to adequately suppress recurrence[96]. While current guidelines generally discourage routine additional ablations such as substrate modification in persistent AF due to inconsistent evidence [102], our subgroup analysis provides new insights. Specifically, we found that additional ablation strategies yielded favorable outcomes in the persistent AF cohort, suggesting that substrate modification and other adjunctive techniques may offer incremental benefit in selected patients. These findings highlight the potential for individualized approaches, particularly when patient selection and procedural technique are optimized. It must be mentioned that our results should be interpreted with caution, given the heterogeneity of included studies, and the fact that no subgroup analysis was done given the smaller number of studies for each specific technique. Further limitations are also applicable to our study. Firstly, significant variations existed in ablation techniques across the included studies. Different centers employed distinct methods for pulmonary vein isolation, including pulmonary vein isolation and pulmonary vein antrum isolation. Some studies, such as Lin et al., incorporated linear ablation following PVI, while others varied in their approach to complex fractionated atrial electrogram (CFAE) ablation. For instance, Verma et al. limited CFAE ablation to the anterior left atrium and septum, whereas Deisenhofer et al. performed a more extensive CFAE ablation involving both atria. Secondly, the observed efficacy is likely to be influenced by the monitoring strategies used, which may contribute to perceived differences, especially in strategies such as Autonomic Modulation that have only been examined in a limited number of studies. Although subgroup analysis suggests Autonomic Modulation is the most effective adjunctive strategy, the relatively small number of studies and sample size for this technique limits the strength of this conclusion and warrants cautious interpretation. Moreover, Autonomic Modulation includes various techniques such as ganglionated plexi ablation and renal denervation which can have varied outcomes and a separate subgroup analysis was not done given the smaller number of trials available for these individual techniques. In this regard, Substrate Modification has the largest patient population that we have analyzed, and claims about its efficacy as an additional ablation strategy can be made with more confidence, even though, of all the ablation techniques studied, it seemingly presents with the lowest efficacy. Another limitation is the variability in antiarrhythmic drug use across studies. For example, Verma et al. permitted a small proportion of patients to remain on AADs during follow-up. However, this was justified by the study protocol, which required AAD discontinuation after two months. Additionally, 96% of patients classified as having a successful post-ablation outcome were off AADs, and the small percentage still on medication was evenly distributed between groups. Importantly, our analysis does not account for the variability in power settings for radiofrequency ablation, nor does it differentiate between ablation modalities (e.g., radiofrequency, cryoballoon, pulsed field ablation), which may impact outcomes given the evolving role of PFA in clinical practice [101]. Lastly, restricting the analysis to published studies may have introduced publication bias, favoring outcomes reported by more experienced centers and potentially overestimating the benefits of ablation. Other factors, such as differences in AF subtypes (paroxysmal AF, persistent AF), the temporal hetrogeniety (studies spanning almost two decades have been included) and the duration of the blanking period, further contribute to variability in results, limiting their generalized applicability. On the other hand, the fact that the included randomized controlled trials (RCTs) enrolled both paroxysmal and non-paroxysmal AF patients, utilized various ablation strategies, and employed different energy sources supports the relevance of the results in real-world settings. Moreover, while the definition of > 30 s of arrhythmia as a monitoring endpoint remains a subject of debate, it was used in our analysis as well since it has been consistently used in prior RCTs. Lastly, most of the studies included in this analysis had a moderate risk of bias attributable to the nature of interventions, which did not allow for participants or clinicians. In conclusion, our meta-analysis demonstrated that combining pulmonary vein isolation (PVI) with additional ablation techniques significantly reduces the risk of atrial fibrillation (AF) recurrence compared to PVI alone. Autonomic modulation (AM) showed the lowest incidence of recurrence, followed by linear ablation (LA) and nPVI-te. However, variations in ablation techniques, monitoring strategies, and antiarrhythmic drug use across studies must be considered when interpreting these results, and more standardized trials are needed to determine better individual applicability. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4.